Header Logo

Connection

Reina Haque to Humans

Back to Details
This is a "connection" page, showing publications Reina Haque has written about Humans.
Reina Haque
Connection Strength
1.565
Humans
  1. Comorbidity burden and risk of second primary non-breast cancer in breast cancer survivors. Cancer Epidemiol. 2025 Aug; 97:102867.
    View in: PubMed
    Score: 0.069
  2. Persistent prescription opioid use and all-cause mortality following the first-year breast cancer survivorship. JNCI Cancer Spectr. 2025 Apr 30; 9(3).
    View in: PubMed
    Score: 0.069
  3. Developing a Community-Oriented and Place-Based Strategy to Improve COVID-19 Vaccine Accessibility. Perm J. 2023 03 15; 27(1):103-112.
    View in: PubMed
    Score: 0.059
  4. Influence of Comorbidity Burden, Socioeconomic Status, and Race and Ethnicity on Survival Disparities in Patients With Cancer. Cancer Control. 2023 Jan-Dec; 30:10732748231204474.
    View in: PubMed
    Score: 0.058
  5. Association of Physical Activity With Risk of Mortality Among Breast Cancer Survivors. JAMA Netw Open. 2022 11 01; 5(11):e2242660.
    View in: PubMed
    Score: 0.058
  6. Antidepressant medication use and prostate cancer recurrence in men with depressive disorders. Cancer Causes Control. 2022 Nov; 33(11):1363-1372.
    View in: PubMed
    Score: 0.057
  7. Sleep medication use and risk of fractures in breast cancer survivors. Breast Cancer Res Treat. 2021 Dec; 190(3):541-548.
    View in: PubMed
    Score: 0.053
  8. Patterns of overall mortality by race/ethnicity and socioeconomic status in insured cancer patients in Southern California. Cancer Causes Control. 2021 Jun; 32(6):609-616.
    View in: PubMed
    Score: 0.052
  9. SARS-CoV-2 Testing, Positivity Rates, and Healthcare Outcomes in a Cohort of 22,481 Breast Cancer Survivors. JCO Clin Cancer Inform. 2021 02; 5:168-175.
    View in: PubMed
    Score: 0.051
  10. Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations. Gynecol Oncol. 2020 05; 157(2):521-528.
    View in: PubMed
    Score: 0.048
  11. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer. 2017 Oct 10; 117(8):1233-1240.
    View in: PubMed
    Score: 0.040
  12. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. J Am Pharm Assoc (2003). 2017 May - Jun; 57(3):303-310.e2.
    View in: PubMed
    Score: 0.039
  13. Cardiovascular Disease After Aromatase Inhibitor Use. JAMA Oncol. 2016 Dec 01; 2(12):1590-1597.
    View in: PubMed
    Score: 0.038
  14. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
    View in: PubMed
    Score: 0.036
  15. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
    View in: PubMed
    Score: 0.036
  16. A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care. 2015 Apr; 53(4):380-5.
    View in: PubMed
    Score: 0.034
  17. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015 Jul 01; 121(13):2147-55.
    View in: PubMed
    Score: 0.034
  18. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014 Apr; 7(4):378-87.
    View in: PubMed
    Score: 0.031
  19. Comorbidities and cardiovascular disease risk in older breast cancer survivors. Am J Manag Care. 2014; 20(1):86-92.
    View in: PubMed
    Score: 0.031
  20. Association of body mass index and prostate cancer mortality. Obes Res Clin Pract. 2014 Jul-Aug; 8(4):e374-81.
    View in: PubMed
    Score: 0.030
  21. Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies. Cancer Epidemiol Biomarkers Prev. 2013 Feb; 22(2):313-6.
    View in: PubMed
    Score: 0.029
  22. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012 Dec; 1(3):318-27.
    View in: PubMed
    Score: 0.029
  23. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21(10):1848-55.
    View in: PubMed
    Score: 0.029
  24. Sleep disturbance, inflammation and depression risk in cancer survivors. Brain Behav Immun. 2013 Mar; 30 Suppl:S58-67.
    View in: PubMed
    Score: 0.028
  25. Preventive care and health behaviors among overweight/obese men in HMOs. Am J Manag Care. 2012 Jan; 18(1):25-32.
    View in: PubMed
    Score: 0.027
  26. Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 2011 Oct; 20(10):2120-6.
    View in: PubMed
    Score: 0.027
  27. Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010 May; 16(5):351-60.
    View in: PubMed
    Score: 0.024
  28. Correlates of prostate-specific antigen testing in a large multiethnic cohort. Am J Manag Care. 2009 Nov; 15(11):793-9.
    View in: PubMed
    Score: 0.023
  29. Correlates of screening sigmoidoscopy use among men in a large nonprofit health plan. Cancer. 2007 Jul 15; 110(2):275-81.
    View in: PubMed
    Score: 0.020
  30. Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett. 2005 Apr 18; 221(1):61-5.
    View in: PubMed
    Score: 0.017
  31. An automated data algorithm to distinguish screening and diagnostic colorectal cancer endoscopy exams. J Natl Cancer Inst Monogr. 2005; (35):116-8.
    View in: PubMed
    Score: 0.017
  32. The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Gu?rin in Treating Nonmuscle-Invasive Bladder Cancer. J Urol. 2024 Sep; 212(3):420-430.
    View in: PubMed
    Score: 0.016
  33. Arsenic in drinking water and skin lesions: dose-response data from West Bengal, India. Epidemiology. 2003 Mar; 14(2):174-82.
    View in: PubMed
    Score: 0.015
  34. Smoking Behaviors and Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer in the Be-Well Study. JAMA Netw Open. 2022 11 01; 5(11):e2244430.
    View in: PubMed
    Score: 0.014
  35. Accelerated mononuclear cell telomere attrition in breast cancer survivors with depression history: A 2-year longitudinal cohort study. Cancer. 2022 Aug 15; 128(16):3109-3119.
    View in: PubMed
    Score: 0.014
  36. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations. Gynecol Oncol. 2020 12; 159(3):804-810.
    View in: PubMed
    Score: 0.012
  37. Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 02; 59(2):321-329.
    View in: PubMed
    Score: 0.010
  38. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454.
    View in: PubMed
    Score: 0.010
  39. Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample. Breast Cancer Res Treat. 2017 01; 161(2):375-384.
    View in: PubMed
    Score: 0.010
  40. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619.
    View in: PubMed
    Score: 0.009
  41. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst. 2016 Mar; 108(3).
    View in: PubMed
    Score: 0.009
  42. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat. 2015 Dec; 154(3):609-16.
    View in: PubMed
    Score: 0.009
  43. Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival. AIDS. 2015 Sep 24; 29(15):1943-51.
    View in: PubMed
    Score: 0.009
  44. Statins and hip fracture risk in men: a population-based case-control study. Ann Epidemiol. 2015 Nov; 25(11):844-8.
    View in: PubMed
    Score: 0.009
  45. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
    View in: PubMed
    Score: 0.009
  46. A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection. Clin Cancer Res. 2015 Mar 15; 21(6):1429-37.
    View in: PubMed
    Score: 0.008
  47. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62.
    View in: PubMed
    Score: 0.008
  48. Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat. 2014 Jul; 146(2):401-9.
    View in: PubMed
    Score: 0.008
  49. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30.
    View in: PubMed
    Score: 0.008
  50. Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. Prostate. 2013 Sep; 73(13):1371-7.
    View in: PubMed
    Score: 0.007
  51. Fracture risk in older, long-term survivors of early-stage breast cancer. J Am Geriatr Soc. 2013 Jun; 61(6):888-95.
    View in: PubMed
    Score: 0.007
  52. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
    View in: PubMed
    Score: 0.007
  53. Impact of type 2 diabetes on lower urinary tract symptoms in men: a cohort study. BMC Urol. 2013 Feb 20; 13:12.
    View in: PubMed
    Score: 0.007
  54. Validation of AJCC TNM staging for breast tumors diagnosed before 2004 in cancer registries. Cancer Causes Control. 2012 Sep; 23(9):1587-91.
    View in: PubMed
    Score: 0.007
  55. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clin Cancer Res. 2012 Sep 01; 18(17):4702-12.
    View in: PubMed
    Score: 0.007
  56. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
    View in: PubMed
    Score: 0.007
  57. A comparison of lifestyle and behavioral cardiovascular disease risk factors between Asian Indian and White non-Hispanic men. Ethn Dis. 2012; 22(2):168-74.
    View in: PubMed
    Score: 0.007
  58. Evaluating racial/ethnic disparities in lower urinary tract symptoms in men. J Urol. 2012 Jan; 187(1):185-9.
    View in: PubMed
    Score: 0.007
  59. Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction. J Urol. 2011 Apr; 185(4):1388-93.
    View in: PubMed
    Score: 0.006
  60. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One. 2010 Jan 15; 5(1):e8736.
    View in: PubMed
    Score: 0.006
  61. Red wine consumption and risk of prostate cancer: the California men's health study. Int J Cancer. 2010 Jan 01; 126(1):171-9.
    View in: PubMed
    Score: 0.006
  62. Red wine consumption not associated with reduced risk of colorectal cancer. Nutr Cancer. 2010; 62(6):849-55.
    View in: PubMed
    Score: 0.006
  63. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
    View in: PubMed
    Score: 0.006
  64. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
    View in: PubMed
    Score: 0.006
  65. Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):2979-83.
    View in: PubMed
    Score: 0.006
  66. Generational status and duration of residence predict diabetes prevalence among Latinos: the California Men's Health Study. BMC Public Health. 2009 Oct 19; 9:392.
    View in: PubMed
    Score: 0.006
  67. Racial disparities in erectile dysfunction among participants in the California Men's Health Study. J Sex Med. 2009 Dec; 6(12):3433-9.
    View in: PubMed
    Score: 0.006
  68. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009 Jul 30; 69(11):1445-57.
    View in: PubMed
    Score: 0.006
  69. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010 Jan; 63(1):64-74.
    View in: PubMed
    Score: 0.006
  70. Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009 Jul 01; 27(19):3211-6.
    View in: PubMed
    Score: 0.006
  71. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA. 2008 Oct 08; 300(14):1660-4.
    View in: PubMed
    Score: 0.005
  72. Abstracting height and weight from medical records, and breast cancer pathologic factors. Cancer Causes Control. 2008 Dec; 19(10):1217-26.
    View in: PubMed
    Score: 0.005
  73. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2218-25.
    View in: PubMed
    Score: 0.005
  74. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007 Nov; 20(11):1149-55.
    View in: PubMed
    Score: 0.005
  75. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008 Feb; 107(3):397-403.
    View in: PubMed
    Score: 0.005
  76. Children's intellectual function in relation to arsenic exposure. Epidemiology. 2007 Jan; 18(1):44-51.
    View in: PubMed
    Score: 0.005
  77. Blood concentrations of methionine, selenium, beta-carotene, and other micronutrients in a case-control study of arsenic-induced skin lesions in West Bengal, India. Environ Res. 2006 Jun; 101(2):230-7.
    View in: PubMed
    Score: 0.004
  78. Bronchiectasis in persons with skin lesions resulting from arsenic in drinking water. Epidemiology. 2005 Nov; 16(6):760-5.
    View in: PubMed
    Score: 0.004
  79. Decrements in lung function related to arsenic in drinking water in West Bengal, India. Am J Epidemiol. 2005 Sep 15; 162(6):533-41.
    View in: PubMed
    Score: 0.004
  80. Nutritional factors and susceptibility to arsenic-caused skin lesions in West Bengal, India. Environ Health Perspect. 2004 Jul; 112(10):1104-9.
    View in: PubMed
    Score: 0.004

© 2025 Kaiser Permanente

Your Privacy Choices